microRNA-141 oligonucleotides for prostate cancer stem cell suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective ways to utilize microRNA-141 as a tumor suppressor to inhibit prostate cancer stem cell proliferation and metastasis, which are refractory to conventional therapeutics.
Innovation Solution
Administering a pharmacologically effective amount of microRNA-141 oligonucleotide or mimic to increase its expression in cancer cells, thereby inhibiting proliferation, invasion, and metastasis by targeting specific genes and pathways involved in tumor growth and epithelial to mesenchymal transition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If microRNA-141 is administered to suppress tumor growth and metastasis, then cancer cell proliferation and metastasis are inhibited, but the complexity of the treatment method increases due to the need for specific oligonucleotide delivery systems
Solution Approach 1:
The patent uses microRNA-141 oligonucleotides as intermediary molecules that specifically bind to and suppress oncogenic targets in cancer cells. These oligonucleotides act as mediators between the administered treatment and the cancer stem cells, providing targeted suppression of tumor growth and metastasis while minimizing off-target effects.
Solution Approach 2:
The patent employs microRNA-141 which targets specific gene expression parameters in cancer cells, changing the expression levels of oncogenic targets such as CD44, ALDH1A1, and other stem cell markers. This parameter-based approach allows selective suppression of cancer stem cell properties without affecting normal cells.
2Reliability
If microRNA-141 oligonucleotide is used to target cancer stem cells, then proliferation and metastasis are suppressed, but the difficulty of detecting and measuring the treatment effect increases due to the molecular nature of the intervention
Solution Approach 1:
The patent utilizes the endogenous processing and amplification of microRNA-141 within cancer cells as a feedback mechanism. The oligonucleotides are processed by the cellular machinery, leading to sustained suppression of target genes. This self-amplifying feedback ensures persistent therapeutic effect that can be monitored through standard molecular biology techniques such as qPCR and Western blotting.
Solution Approach 2:
The patent replaces mechanical or surgical intervention with molecular-level intervention using microRNA oligonucleotides. Instead of physical removal or destruction of tumors, the treatment uses biochemical mechanisms to suppress cancer stem cell function, allowing detection through molecular markers rather than requiring invasive procedures.
Data Source
AI summary
Provided herein are methods of treating a cancer in an individual. A microRNA-141 oligonucleotide or mimic that increases the expression of microRNA-141 in the cancer cell is administered to the individual. Also provided is a method of inhibiting proliferation of a cancer cell and treating a cell associated with a cancer. The cell is contacted with the microRNA-141 oligonucleotide or mimic.